Bone morphogenetic protein-2 exhibits therapeutic benefits for osteonecrosis of the femoral head through induction of cartilage and bone cells
- Chunhui Wang
- Huimei Zang
- Dongsheng Zhou
Affiliations: Department of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of Cardiovascular Medicine, Shandong University Qilu Hospital Research Center for Cell Therapy, Key Laboratory of Cardiovascular Remodeling and Function, Jinan, Shandong 250012, P.R. China
- Published online on: March 9, 2018 https://doi.org/10.3892/etm.2018.5941
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Osteonecrosis of the femoral head is an orthopedic disease caused by femoral head damage or insufficient blood supply, which leads to the death of bone cells and bone marrow. Osteonecrosis of the femoral head leads to changes in the structure of the femoral head, femoral head collapse and joint dysfunction. Bone morphogenetic protein‑2 (BMP‑2) exhibits beneficial effects on bone formation, repair and angiogenesis at the femoral head. In the present study, the therapeutic effects of recombinant human BMP‑2 containing an Fc fragment (rBMP‑2/Fc) were investigated on a steroid induced mouse model of osteonecrosis of the femoral head. Bone cell viability was used to determine the in vitro effects of rBMP‑2/Fc. The therapeutic efficacies of rBMP‑2/Fc on mice with osteonecrosis of the femoral head were evaluated using clinical arthritis scores. The expression levels of inflammatory factors in the mice were analyzed by reverse transcription‑quantitative polymerase chain reaction. Histological analysis was used to evaluate the effects of rBMP‑2/Fc on the femoral head. The results revealed that rBMP‑2/Fc treatment significantly increased the IL‑6, IL‑10, vascular endothelial growth factor and macrophage colony‑stimulating factor expression levels in synovial cells compared with the control group (P<0.01). Furthermore, it was observed that rBMP‑2/Fc significantly improved the viability and growth of synovial cells (P<0.01) through the nuclear factor (NF)‑κB signaling pathway. Treatment with rBMP‑2/Fc significantly decreased receptor activator of NF‑κB ligand expression levels. Furthermore, in vivo experiments demonstrated that rBMP‑2/Fc treatment markedly relieved the arthralgia and damage caused by osteonecrosis of the femoral head. In conclusion, rBMP‑2/Fc treatment may be beneficial for articular cartilage repair by the upregulation of angiogenesis factors through the down regulation of the NF‑κB signaling pathway in mice with osteonecrosis of the femoral head. This preclinical data suggests that rBMP‑2/Fc may be a promising novel agent for treatment of osteonecrosis of the femoral head.